Literature DB >> 17558898

Determination of alpha-synuclein concentration in human plasma using ELISA.

A Winther Fjorback1, K Varming, P Henning Jensen.   

Abstract

The nerve cell protein alpha-synuclein is important in Parkinson's disease and dementia with Lewy bodies, and its expression levels are directly linked to development of the diseases. Quantification of the plasma level of alpha-synuclein may therefore be important as a biomarker for disease susceptibility. We present a quantitative measurement of alpha-synuclein in the plasma of healthy control subjects in relation to their age using a novel enzyme-linked immunosorbent assay (ELISA). The plasma concentration among the 44 blood donors displayed a median of 5.6 microg/L (range 2.1-19.4 microg/L) with a narrow distribution (25 % and 75 % percentiles, 4.0 and 7.2 microg/L) and there was no correlation with age and gender. This narrow concentration range and the ease of measuring the quantitative ELISA support future investigations of plasma alpha-synuclein in relation to neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558898     DOI: 10.1080/00365510601161497

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  15 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  α-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia.

Authors:  Erik Su; Michael J Bell; Stephen R Wisniewski; P David Adelson; Keri L Janesko-Feldman; Rosanne Salonia; Robert S B Clark; Patrick M Kochanek; Valerian E Kagan; Hülya Bayır
Journal:  Dev Neurosci       Date:  2010-12-02       Impact factor: 2.984

3.  Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease.

Authors:  Min Shi; Cyrus P Zabetian; Aneeka M Hancock; Carmen Ginghina; Zhen Hong; Dora Yearout; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; James B Leverenz; Jing Zhang
Journal:  Neurosci Lett       Date:  2010-06-09       Impact factor: 3.046

4.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

Authors:  Zhen Hong; Min Shi; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; James B Leverenz; Geoffrey Baird; Thomas J Montine; Aneeka M Hancock; Hyejin Hwang; Catherine Pan; Joshua Bradner; Un J Kang; Poul H Jensen; Jing Zhang
Journal:  Brain       Date:  2010-02-15       Impact factor: 13.501

5.  Alpha-synuclein in alpha-helical conformation at air-water interface: implication of conformation and orientation changes during its accumulation/aggregation.

Authors:  Chengshan Wang; Nilam Shah; Garima Thakur; Feimeng Zhou; Roger M Leblanc
Journal:  Chem Commun (Camb)       Date:  2010-08-16       Impact factor: 6.222

6.  The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged Humans.

Authors:  Manoj Kumar Pandey
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702

7.  The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.

Authors:  Mohamed-Bilal Fares; Nadine Ait-Bouziad; Igor Dikiy; Martial K Mbefo; Ana Jovičić; Aoife Kiely; Janice L Holton; Seung-Jae Lee; Aaron D Gitler; David Eliezer; Hilal A Lashuel
Journal:  Hum Mol Genet       Date:  2014-04-11       Impact factor: 6.150

8.  Conversion of natively unstructured α-synuclein to its α-helical conformation significantly attenuates production of reactive oxygen species.

Authors:  Binbin Zhou; Yuanqiang Hao; Chengshan Wang; Ding Li; You-Nian Liu; Feimeng Zhou
Journal:  J Inorg Biochem       Date:  2012-09-08       Impact factor: 4.155

9.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.

Authors:  Jon B Toledo; Ane Korff; Leslie M Shaw; John Q Trojanowski; Jing Zhang
Journal:  Acta Neuropathol       Date:  2013-06-29       Impact factor: 17.088

10.  Clinical and multimodal biomarker correlates of ADNI neuropathological findings.

Authors:  Jon B Toledo; Nigel J Cairns; Xiao Da; Kewei Chen; Deborah Carter; Adam Fleisher; Erin Householder; Napatkamon Ayutyanont; Auttawut Roontiva; Robert J Bauer; Paul Eisen; Leslie M Shaw; Christos Davatzikos; Michael W Weiner; Eric M Reiman; John C Morris; John Q Trojanowski
Journal:  Acta Neuropathol Commun       Date:  2013-10-09       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.